Prostate Cell News 8.17 May 12, 2017 | |
| |
TOP STORYDual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition The authors investigated the preclinical effects of UNC1999, a dual inhibitor of EZH2 and EZH1, in combination with proteasome inhibitors on multiple myeloma (MM) and prostate cancer. In vitro and in vivo efficacy of UNC1999 and the combination with proteasome inhibitors was evaluated in MM cell lines, primary patient cells and in a xenograft model. [Clin Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHRET Signaling in Prostate Cancer RET was expressed in all prostate cancer cell lines. GFRα1 was only expressed in 22Rv1 cells, which is the only line that responds to exogenous GDNF. In contrast, all cell lines responded to GDNF plus GFRα1. Conditioned medium from dorsal root ganglia contained secreted GFRα1 and promoted transformation related phenotypes, which can be blocked by anti-GFRα1 antibody. [Clin Cancer Res] Abstract A Novel MicroRNA Regulator of Prostate Cancer Epithelial–Mesenchymal Transition To understand the functional significance of miR-3622a, knockdown and overexpression was performed using non-transformed prostate epithelial and prostate cancer cell lines, respectively, followed by functional assays. The authors’ data demonstrated that endogenous miR-3622a expression is vital to maintain the epithelial state of normal and untransformed prostate cells. [Cell Death Differ] Abstract Oncogenic Activity of Amplified Miniature Chromosome Maintenance 8 in Human Malignancies Increased expression of miniature chromosome maintenance (MCM) 8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumor volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. [Oncogene] Abstract Scientists discovered that a long noncoding RNA (lncRNA) HOXD-AS1 is highly expressed in castration-resistant prostate cancer (CRPC) cells and correlated closely with Gleason score, T stage, lymph nodes metastasis, and progression-free survival. Knockdown of HOXD-AS1 inhibited the proliferation and chemo-resistance of CRPC cells in vitro and in vivo. [Mol Ther] Full Article | Graphical Abstract Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-Deficient Mouse Model of Prostate Cancer Researchers investigated the chemopreventive effect of the phytonutrient withaferin A (WA) on AKT-driven prostate tumorigenesis in a Pten conditional knockout mouse model of prostate cancer. Oral WA treatment was carried out at two different doses and compared to vehicle over 45 weeks. Oral administration of WA for 45 weeks effectively inhibited primary tumor growth in comparison to vehicle controls. [Neoplasia] Full Article Investigators explored the role of second chromosome locus associated with prostate-1 (SChLAP1) in prostate cancer tissues, cell lines and mouse models. The effects of SChLAP1 on miR-198 and MAPK1 were specifically examined. They found that SChLAP1 expression was significantly increased in prostate cancer cells and tissues. Knockdown of SChLAP1 promoted apoptosis and inhibited cell proliferation and invasion in vitro and in vivo. [Oncol Res] Full Article Label-Free Isolation of Prostate Circulating Tumor Cells Using Vortex Microfluidic Technology Scientists described the use of the microfluidic Vortex Chip for size-based isolation of circulating tumor cells (CTCs) from 22 patients with advanced prostate cancer and, from an enumeration study on 18 of these patients, found that they can capture CTCs with high purity and efficiency in less than one hour. More atypical large circulating cells were identified in five age-matched healthy donors than in five healthy donors <30 years old. [npj Precision Oncology] Full Article CLINICAL RESEARCHResearchers conducted an open-label, single-arm, Phase I/II clinical trial in patients with castration-resistant prostate cancer (CRPC) to determine the safety and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E). Patients with CRPC who were docetaxel-resistant or could not receive docetaxel treatment were eligible. [Cancer Gene Ther] Full Article | |
| |
REVIEWSReciprocal signaling between prostate stroma and its epithelium are fundamental to organ development and homeostasis. Similarly, interactions between tumor cells and stromal constituents are central to key aspects of carcinogenesis and malignancy growth involving tumor cell invasion, dissemination, and growth in distant sites. [Cold Spring Harb Perspect Med] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSGenomeDx Biosciences announced a collaboration with Color to offer its Color Test, a hereditary cancer risk genetic test that analyzes 30 genes. The collaboration further expands GenomeDx’s broad product offering across prostate cancer. [GenomeDx Biosciences] Press Release Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737 Sierra Oncology, Inc. reported that it has received clearance from regulators in the UK to amend the two ongoing Phase I trials for its Chk1 inhibitor, SRA737. The amended trials will include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition. [Sierra Oncology, Inc.] Press Release NxThera, Inc. announced the company’s Rezūm System has been used to safely and effectively treat more than 10,000 men suffering from benign prostatic hyperplasia across the U.S. and Europe. [NxThera, Inc. (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSChina Cracks Down on Fake Data in Drug Trials Those who submit faked clinical trial data might now go to jail — and in extreme circumstances, be executed — under a new interpretation of China’s criminal code. The policy shift is one of a handful of measures that China is implementing both to speed up its notoriously slow drug-approval process and to keep dangerous and ineffective drugs off the market. [Nature News] Editorial The Secret War against Counterfeit Science China is famous for knock-off DVDs, Louis Vuitton bags and Rolex watches. But counterfeit reagents aren’t on sale in busy public markets. They are sold through sophisticated websites, mixed in with legitimate supplies, and sourced and sold using a network of unwitting partners. [Nature News] Editorial Science Publishers Try New Tack to Combat Unauthorized Paper Sharing The unauthorized sharing of copyrighted research papers is on the rise, say analysts who track the publishing industry. Faced with this problem, science publishers seem to be changing tack in their approach to researchers who breach copyright. [Nature News] Editorial Biotech Execs, Academic Leaders Make Case for NIH Funding at White House Meeting Could the Trump administration be changing its mind about slashing funding for the National Institutes of Health (NIH)? Scientific leaders were optimistic after meeting at the White House with several biotech executives to discuss the “ecosystem” in which federally funded basic research leads to discoveries that companies turn into treatments. [ScienceInsider] Editorial
| |
EVENTSNEW Cold Spring Harbor Stem Cell Biology Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Fellow – Mammalian Stem Cell Biology (NYU School of Medicine) Postdoctoral Fellow – Translational Prostate Cancer Research (Weill Cornell Medicine) Postdoctoral Fellow – Prostate Cancer (University of South Carolina-School of Medicine) Faculty Position – Genitourinary Oncology (Northwestern University) Scientist – Prostate Cancer Research (Dana-Farber Cancer Institute) Postdoctoral Fellow – Cancer Biology (Northwestern University) Postdoctoral Fellow – Prostate Cancer (Johns Hopkins University) Postdoctoral Fellow – Prostate/Pancreatic Cancer (Medical College of Wisconsin) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Prostate Cell News Volume 8.17 | May 12 2017